



PRESS RELEASE

FOR IMMEDIATE DISTRIBUTION

**AmorChem's KNOCK-OUT™ Event:
Where academic Contenders duke it out with industry Heavyweight Champions.
Who will be left standing in the ring?**

Montreal, September 18, 2013. Earlier in the summer, AmorChem, the innovative Quebec-based seed venture capital fund, launched a province-wide call for proposals to participate in its KNOCK-OUT™ Event. Five academic researchers have now been selected as Contenders to participate in the final stage of the Event. On October 2nd, after several weeks of training, the five Contenders will duke it out in the ring against a panel of Heavyweight Champions in order to win a \$500,000 financing from AmorChem.

In the Contenders' corner, anxiously practicing their scientific jabs and technical uppercuts, we have

- Dr. Jay Nadeau from McGill University,
- Dr. Catherine Paradis-Bleau from the University of Montreal,
- Dr. Moutih Rafei from the University of Montreal,
- Dr. John Stagg from the Centre Hospitalier Universitaire de Montréal and Université de Montréal,
- Dr. Jacques P. Tremblay from the Centre Hospitalier Universitaire de Québec and Université Laval.

In the opposite corner, ready to challenge the Contenders with their best knock-out punches, we have our undefeated Heavyweight Champions:

- Dr. Julia Levy, best known for her successful Vancouver-based biotech company QLT inc.,
- Dr. Aled Edwards, CEO of the ground-breaking Structural Genomics Consortium,
- Dr. John Gillard, science entrepreneur from Merck Canada, BioChem Pharma inc. and Aegera Therapeutics inc.,
- Dr. Richard Lesniewski, pharmaceutical industry veteran from Abbott and GlaxoSmithKline.

Mr. Christopher Hall, renowned radio and newspaper columnist and comedian, will be the master of ceremony. As any good boxing referee, he will buffer the blows (with water bottles at the ready!) and cheer on the Contenders.

There can only be one winner, which Contender will be left standing after five rounds in the ring with our Heavyweights? Who will be crowned the champion of the ring? Come and find out at the AmorChem session during the BioContact conference on October 2, 3:30 PM, Salle Grande-Allée, Château Laurier. The AmorChem KNOCK-OUT Event promises to be the go-to event- don't miss out!

The AmorChem KNOCK OUT Event is proudly sponsored by ROBIC, LLP.

ABOUT AMORCHEM

AmorChem L.P. (www.amorchem.com) is a venture capital fund located in Montreal focused on investing in promising life science projects originating from Quebec-based universities and research centres. The principal limited partners of this fund are Investissement-Québec, FIER Partenaires, Fonds de solidarité FTQ and Merck & Co. This fund is the latest addition to the GeneChem portfolio of funds, a fund manager in existence since 1997. AmorChem's innovative business model involves financing research-stage projects to enable them to reach pre-clinical proof-of-concept ("POC") in a semi-virtual mode within 18-24 months. The fund seeks to generate returns through a two-pronged exit strategy: sell projects having reached POC to large biotechnology or pharmaceutical companies; or bundle them into new spin-out companies. AmorChem using external resources will manage the projects. To that effect, AmorChem has established a strategic partnership with the Biotechnology Research Institute in order to access its R&D platforms. In addition, to enabling projects requiring small molecules as tools or drug leads, AmorChem has founded NuChem Therapeutics Inc., a medicinal chemistry contract-research company.

Media Contact for AmorChem

Mélanie Larouche

T 418 521 3771

E melanie.larouche@citoyenoptimum.com

ABOUT ROBIC

Founded in 1892, **ROBIC, LLP** is an internationally renowned firm of lawyers, patent and trade-mark agents specialized in Intellectual Property and Business Law. Headquartered in Montreal, ROBIC is a Canadian firm with more than 175 people including 23 partners and 45 professionals. We provide dynamic and entrepreneurial assistance and representation to clients in executing business transactions in addition to managing, protecting, enforcing and commercialising their intellectual capital.

ABOUT BIOCONTACT

BioContact Quebec 2013: The 19th edition will take place on October 2nd and 3rd 2013, at the Château Laurier in Québec City. Representatives from over 24 biopharmaceutical companies from Canada, the United States and Europe will be attending.
